December 10, 2024 09:00 AM EST
R&D

BioN­Tech re­ports ear­ly sur­vival da­ta for VEGF bis­pe­cif­ic, weeks af­ter buy­ing Chi­nese part­ner

Ayisha Sharma

News Reporter

Last month, BioN­Tech went all-in on VEGF bis­pe­cif­ic an­ti­bod­ies. On Tues­day, to val­i­date its bet, the com­pa­ny shared ear­ly sur­vival da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly to ac­quire can­cer biotech Scor­pi­on, which shares a co-founder with Loxo

J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

#JPM25 live blog: How im­por­tant are this morn­ing’s deals to a biotech re­cov­ery? In­sid­ers weigh in

GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug

Hen­grui and Kail­era’s in­ject­ed in­cretin posts best-in-class obe­si­ty da­ta in Phase 2 tri­al

Gilead taps in­to STAT6 space via $250M deal with Leo Phar­ma

A service from the Financial Times